Repeated injections of either progenitor population resulted in reduced hepatic fibrosis (Figure 4C and D), including a reduction in PSR staining (CMP, 1.94% ± 0.29%; CLP, 2.27% ± 0.13%; vs control, 4.38% ± 0.27% staining; P < .01 both vs control) (Figure 4C) and a reduction in α-SMA staining (CMP, 2.79% ± 0.25%; CLP, 3.69% ± 0.33%; vs control 7.05% ± 0.39% staining; P < .05 both vs control) (Figure 4D). Here, ACTA1 is linked to Hepatic fibrosis.